British journal of haematology · 2014
Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fukushima Takuya, Nomura Shogo, Shimoyama Masanori, Shibata Taro, Imaizumi Yoshitaka, Moriuchi Yoshiyuki, Tomoyose Takeaki, Uozumi Kimiharu, Kobayashi Yukio, Fukushima Noriyasu, Utsunomiya Atae, Tara Mitsutoshi, Nosaka Kisato, Hidaka Michihiro, Uike Naokuni, Yoshida Shinichiro, Tamura Kazuo, Ishitsuka Kenji, Kurosawa Mitsutoshi, Nakata Masanobu, Fukuda Haruhiko, Hotta Tomomitsu, Tobinai Kensei, Tsukasaki Kunihiro
Аннотация
This study evaluated the clinical features of 276 patients with aggressive adult T-cell leukaemia-lymphoma (ATL) in 3 Japan Clinical Oncology Group (JCOG) trials. We assessed the long-term survivors who survived >5 years and constructed a prognostic index (PI), named the JCOG-PI, based on covariates obtained by Cox regression analysis. The median survival time (MST) of the entire cohort was 11 months. In 37 patients who survived >5 years, no disease-related deaths in 10 patients with lymphoma-type were observed in contrast to the 10 ATL-related deaths in other types. In multivariate analysis of 193 patients, the JCOG-PI based on corrected calcium levels and performance status identified moderate and high risk groups with an MST of 14 and 8 months respectively (hazard ratio, 1·926). The JCOG-PI was reproducible in an external validation. Patients with lymphoma-type who survived >5 years might have been cured. The JCOG-PI is valuable for identifying patients with extremely poor prognosis and will be useful for the design of future trials combining new drugs or investigational treatment strategies.